Alternative Endpoints in Phase III Trials Don't Always Mean Boosts to OS, QOL

(MedPage Today) — CHICAGO — Late-phase trials that showed superiority for an experimental intervention on a surrogate endpoint did not necessarily lead to improvements in overall survival (OS) or quality of life (QOL), according to a meta-epidemiologic…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115842

Author :

Publish date : 2025-06-01 21:43:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Alternative Endpoints in Phase III Trials Don’t Always Mean Boosts to OS, QOL

This Diet Pattern Is Linked With Worse Survival in Colon Cancer

Tumor Treating Fields Boost Pancreatic Cancer Survival

Related Posts

Consider Psychologic Evaluation for Children With Urinary Incontinence

Some Hormone Therapies Linked to Young-Onset Breast Cancer

A crucial methane-tracking satellite has died in orbit

ACIP Members Show Inexperience, Lack of Understanding at First Meeting, Experts Say

Senate Passes Trump’s Tax Bill With $1 Trillion in Health Cuts

HHS Confirms Contracts With Springer Nature Have Been Terminated

Consider Psychologic Evaluation for Children With Urinary Incontinence

Some Hormone Therapies Linked to Young-Onset Breast Cancer

A crucial methane-tracking satellite has died in orbit

ACIP Members Show Inexperience, Lack of Understanding at First Meeting, Experts Say

Senate Passes Trump’s Tax Bill With $1 Trillion in Health Cuts

HHS Confirms Contracts With Springer Nature Have Been Terminated

DREAMM-20 Hints at a More Tolerable Path for BCMA-Targeted Therapy in Myeloma

Sleep and Alzheimer’s; NIH Cuts to Brain Research; Novel CTE Report

Categories

Archives